Evidence map›Paper›PMID 26439403›Full record

ArticleScientific reports2015

Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case report.

Alicja M Gruszka, Cristina Rabascio, Laura Cannella, Simona Sammassimo, Giovanna Andreola, Giuliana Gregato, Mario Faretta, Angelica Calleri, Rita De Molfetta, Giancarlo Pruneri and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Alicja M GruszkaDepartment of Experimental Oncology European Institute of Oncology, Milan, Italy.
Cristina RabascioLaboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
Laura CannellaDivision of Hemato-oncology European Institute of Oncology, Milan, Italy.
Simona SammassimoDivision of Hemato-oncology European Institute of Oncology, Milan, Italy.
Giovanna AndreolaDivision of Hemato-oncology European Institute of Oncology, Milan, Italy.
Giuliana GregatoLaboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
Mario FarettaDepartment of Experimental Oncology European Institute of Oncology, Milan, Italy.
Angelica CalleriLaboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
Rita De MolfettaDepartment of Experimental Oncology European Institute of Oncology, Milan, Italy.
Giancarlo PruneriDivision of Pathology, European Institute of Oncology, Milan, Italy.
Francesco BertoliniLaboratory of Hematology-Oncology, European Institute of Oncology, Milan, Italy.
Myriam AlcalayDepartment of Experimental Oncology European Institute of Oncology, Milan, Italy.
European Institute of Oncology · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm underlain by the formation of BCR-ABL1 - an aberrant tyrosine kinase - in the leukaemic blasts. Long-term survival rates in CML prior to the advent of tyrosine kinase inhibitors (TKIs) were dismal, albeit the incidence of secondary malignancies was higher than that of age-matched population. Current figures confirm the safety of TKIs with conflicting data concerning the increased risk of secondary tumours. We postulate that care has to be taken when distinguishing between coexisting, secondary-to-treatment and second in sequence, but independent tumourigenic events, in order to achieve an unbiased picture of the adverse effects of novel treatments. To illustrate this point, we present a case of a patient in which CML and peripheral T-cell lymphoma (PTCL) coexisted, although the clinical presentation of the latter followed the achievement of major molecular response of CML to TKIs.

Indexed as

Antineoplastic AgentsFusion Proteins, bcr-ablHumansImatinib MesylateIn Situ Hybridization, FluorescenceLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLymphoma, T-Cell, PeripheralMaleMiddle AgedProtein Kinase InhibitorsAntineoplastic AgentsBCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablImatinib MesylateProtein Kinase Inhibitors

Identifiers

PMID26439403
PMCPMC4594041
OpenAlexW2419522195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.